NCT01788813View on ClinicalTrials.gov

To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Mild Asthma and Allergic Rhinitis
Interventions
DRUG

GSK2245035

Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks

DRUG

Placebo

Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks

Trial Locations (1)

K7L 2V7

GSK Investigational Site, Kingston

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01788813 - To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies | Biotech Hunter | Biotech Hunter